FEATURED ARTICLES

• Simplifying EV/Exosome Research & Development

  Modern solutions are continuing to be developed to help those working in biologics overcome historic Exosomes / Extracellular Vesicles challenges.

• Build Support In The Early Days Of Advanced Therapy Entrepreneurship

  While more biotech companies are entering the market, advanced therapy startups can still benefit greatly from product and service options that help address challenges in the MSC or EV / exosome space.

• Time To Think Globally With Locally Acting Anti-Fibrotic Therapies

  Take a look at important information and data from PubMed publications regarding cancer and fibrosis research and as well as learning about MSCs & their EVs/Exosomes.

• On The Exosome/Extracellular Vesicle Frontier, Choose Your Own Adventure

  Gain insight into the importance of scalability for future clinical products made from extracellular vesicles, the quality of peer-reviewed extracellular vesicle/exosome science, and more.

• RoosterBio At ASGCT-2023: Confidently Crowing In A Crowd Of CRISPRs, Capsids, & CARs

  Explore the highlights of ASGCT-2023 and how RoosterBio uniquely contributed knowledge related to EVs and/or exosomes that benefitted those in attendance.

• Genetic Engineering Medium Aiding The Transfection Of MSCs With siRNA

  A newly developed genetic engineering medium is fueling the development of cell- and extracellular vesicle-based therapies.

• Mitochondria Transplantation Therapy Advancements

  Did you know that mitochondrial transplantation therapies have already been tried in humans and that there’s a firm rationale for this biomedical technology?

• Unlock The Therapeutic Potential Of MSC-Derived Exosomes

  Explore overcoming the challenges of MSC and EV Production and how bone marrow-MSC EVs with anti-inflammatory activity are being used to treat retinal degeneration and traumatic brain injuries.

• Scalable hMSC-Derived Extracellular Vesicles Production

  The need for a single platform that assists EV manufacturers in meeting necessary criteria is driving technology innovations, including work on structured fixed-bed bioreactors.

• MISEV Guidelines Inspire Fledgling EV/Exosome Analytics Services

  Knowing the MISEV characterization guideline will allow your researchers to report EV studies in a uniform, transparent manner allowing for data comparison and reproducibility across different labs.

• EV Analytics: Know Your Process & Define Your Product

  Find out how EV analytics will help you analyze your process and define your product, while learning about EV manufacturing strategies and MISEV guidelines.

• Gifts To Solve Ex Vivo Gene Delivery Challenges

  Explore the tricky challenge of gene transfer into primary cells, along with the impact of genetic engineering on the next wave of cell and exosomes advanced therapies and other developments.

• Solving Challenges In Cell Engineering For Advanced Therapies

  Explore ways to make establishing MSCs and Exosomes within programs, scaling them for product and process development, and translating them into the clinic easier.

• The 'Champagne' Of Human Umbilical Cord Cells?

  Learn about a novel method to obtain unique HUCPVs and how premium quality hUC-MSCs drive innovative translational research.

• Expanding Into New Fields Of “Cell-Grow-Culture” For mRNA Transfection

  Learn about one path forward to navigate the pitfalls with mRNA transfection and a medium to assist in lentivirus-mediated transduction of human mesenchymal stromal/stem cells (hMSCs).

• Enhancing Lentiviral And AAV Transduction Of T Cells

  Learn about new data that highlights exciting uses for future immunotherapy studies.

• When The hMSC Meets The AAV

  Learn more about plausible benefits of AAV’s use in concert with hMSCs, and how a complete genetic engineering medium was expanded beyond lentivirus.

• Accelerate MSC And Exosome Therapies Into The Clinic

  Learn how to incorporate standardized cell banks & right-scaled processes into your experimental design for rapid implementation & robust, reproducible results.

• The Story Behind The Media

  Learn more about a system that fuels the rapid commercialization of scalable regenerative cures.

• Time To Scratch The “30-Year Itch” From MSCs’ Questions

  Explore some of the questions and theories behind why, after compelling pre-clinical and human safety data, MSC therapeutics are not progressing faster.